Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

96results about How to "Avoid peaks and valleys" patented technology

Stone needle energy mud matrix, stone needle energy mud containing matrix and preparation method of stone needle energy mud

The invention relates to a stone needle energy mud matrix, stone needle energy mud containing the matrix and a preparation method of the stone needle energy mud. The matrix consists of the following raw materials in parts by weight: 200-300 parts of stone needle powder, 100-200 parts of volcanic mud, 50-100 parts of far-infrared ceramic powder, 50-100 parts of tourmaline powder, 500-800 parts of beeswax, 10-50 parts of an exothermal agent, 50-100 parts of rosin and 50-100 parts of glycerol; the stone needle energy mud consists of 1010-1750 parts of the stone needle energy mud matrix as well as the following Chinese herbal medicines: 20-30 parts of black ants, 5-10 parts of roasted pangolin scales, 15-20 parts of radix aconiti preparata and the like; and and the preparation method comprises the following steps: crushing the Chinese herbal medicines and uniformly stirring the crushed Chinese herbal medicines with the stone needle energy mud matrix. The stone needle energy mud matrix disclosed by the invention has the beneficial effects that the stone needle energy mud matrix can improve a medicine availability, avoid side effects caused by gastrointestinal administration, enhance therapeutical effect and achieve point transdermal application so as to rapidly and effectively reach focuses.
Owner:河北鹊神生物科技有限公司

Control releasing venlafaxine hydrochloride tablet and its prepn

The present invention discloses one kind of control releasing venlafaxine hydrochloride tablet and its preparation process. The control releasing venlafaxine hydrochloride tablet consists of medicine core of venlafaxine hydrochloride and semi-permeable coating with pores. The medicine core consists of venlafaxine hydrochloride 75 weight portions, stuffing 30-250 weight portions, osmotic pressure promoter 1-50 weight portions, adhesive 1-20 weight portions and lubricant 0.1-20 weight portions. The preparation has reasonable composition, excellent control releasing effect, long effective time, less side effect on gastrointestinal tract, less differential personal effect, high safety and good compliance.
Owner:CHENGDU KANGHONG PHARMA GRP

Cubic liquid crystal in-situ gel injection of local anesthetic, and preparation method of injection

The invention relates to cubic liquid crystal in-situ gel injection of local anesthetic, and a preparation method of the injection. The injection is prepared from the local anesthetic, a liquid crystal material and an organic solvent and / or a release regulator; the local anesthetic is amide local anesthetic and the mass concentration of the local anesthetic is 0.1 to 8 w / w%; the organic solvent is an organic solvent which is mutually soluble with water, the liquid crystal material is mono-oleic acid glycerolipid, and the mass ratio of the liquid crystal material to the organic solvent is (1-9):1; and the release regulator is selected from at least one of medium chain triglyceride, oleic acid, tocopherol and tocopheryl acetate, and the mass concentration of the release regulator is 0 to 30 w / w%. The cubic liquid crystal in-situ gel injection of the local anesthetic has very good long-acting sustained release effect, low sudden release raten high compliance and small adverse effect, can reduce administration times and can avoid the peak valley phenomenon.
Owner:GUANGZHOU NEWORLD PHARMA CO LTD

Traditional Chinese medicine composition for treating necrotic enteritis of chickens and preparation method thereof

The invention discloses a traditional Chinese medicine composition for treating necrotic enteritis of chickens. The traditional Chinese medicine composition is mainly prepared from golden cypress, fructus aurantii, magnolia obavata, radix linderae, pericarpium arecae, rhizoma atractylodis macrocephalae, poria cocos, rhizoma dioscoreae, fructus crataegi, radix sophorae flavescentis, medicated leaven, radix sileris, herba patriniae, radix pulsatillae, moutan bark, selfheal, radix glycyrrhizae, nauclea officinalis, folium perillae, cassia occidentalis, radix astragali, pericarpium granati, monkshood, herba taraxaci, bunge corydalis herb, red triadica sebifera and radix scutellariae. A preparation method of the traditional Chinese medicine composition for treating necrotic enteritis of chickens comprises the following steps: superfine grinding, mixing in batches, extracting, combining and concentrating. The traditional Chinese medicine composition has the advantages that the curative effect is effective, the medicine resistance is avoided, the medicine residue is avoided, and the traditional Chinese medicine composition is capable of treating necrotic enteritis of chickens, improving intestinal environment of chickens and enhancing immunity of chickens.
Owner:RONGXIAN XIANGYI FARMING CO LTD

Phlegm dissolving and cough quenching paste

InactiveCN104225126AFlat drug concentration curveImprove the body's non-specific immunityRespiratory disorderSheet deliveryQuenchingAsthma
The invention discloses a phlegm dissolving and cough quenching paste and belongs to the technical field of medical preparations. The traditional Chinese medicine raw materials consist of the following substances in part by weight: 2-10 of sinapis alba, 1-6 of ephedra, 1-5 of euphorbia kansui, 1-4 of araceae, 0.5-4 of corydalis, 0.5-4 of asarum and 1-4 of castor bean oil. The phlegm dissolving and cough quenching paste is prepared by the method that traditional Chinese medicines in the traditional Chinese medicine raw materials except the castor bean oil are pulverized, blended with the castor bean oil, uniformly mixed and pasted on rubberized fabric. The phlegm dissolving and cough quenching paste has the functions of ventilating the lung, relieving cough, dispelling phlegm and preventing asthma and is mainly used for treating chronic obstructive pulmonary diseases and cough symptoms, such as cough, phlegm coughing and breath shortness.
Owner:STATE GRID CORP OF CHINA +1

Dry suspension containing cefixime liposome and preparation method thereof

The invention relates to cefixime liposome and preparation method therefore as well as dry suspension containing the cefixime liposome. The dry suspension is composed of the cefixime liposome and pharmaceutically acceptable carriers, wherein the cefixime liposome comprises the following components in parts by weight: 1 part of cefixime, 1.25-5 parts of hydrogenated soybean lecithin, 1.25-5 parts of hydrogenated yolk lecithin, 2.5-10 parts of cholesterol and 0.1-5 parts of polysorbate 80. The dry suspension not only accords with the requirements of Chinese pharmacopoeia, but also has the advantages of better storage stability in normal temperature, faster effect exertion and obviously improved bioavailability in comparison with the common cefixime medicaments.
Owner:王丽燕

Compound sustained-release tablet of epalrestat and sitagliptin or pharmaceutically acceptable salt thereof and preparation method thereof

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a compound sustained-release tablet of epalrestat and sitagliptin or pharmaceutically acceptable salt thereof and a preparation method thereof. The compound sustained-release tablet contains epalrestat, sitagliptin or pharmaceutically acceptable salt thereof and / or hydrate of the salt, anhydrous calcium hydrophosphate, a framework sustained-release material and other pharmaceutical excipients. The compound sustained-release tablet can be a single-layer tablet or a double-layer tablet, and is used for treating type 2 diabetes, especially peripheral neuropathy caused by the type 2 diabetes. The compound composition is prepared into the sustained-release tablet, so that the synergistic interaction time of the two active ingredients can be exerted and prolonged, the stimulation effect of the medicine on gastrointestinal tracts can be reduced, the compliance of patients can be improved, the peak valley phenomenon of a common preparation in blood after the common preparation is taken is avoided, the occurrence of adverse reactions is reduced, and the medication safety is improved.
Owner:乐普制药科技有限公司

Novel enteric controlled-release tablet preparation and preparation method thereof

The invention discloses a novel controlled-release preparation based on osmotic pump preparation and a preparation method thereof. The controlled-release preparation comprises a medicine tablet core containing active medicine, a semipermeable film coating coated on the outer layer of the medicine tablet core and provided with small holes, and an enteric coating arranged at the outermost layer, wherein the medicine tablet core comprises 20-70 parts of danshinolic acid B, 50-250 parts of loading agent, 1-120 parts of osmotic pressure accelerant, 1-20 parts of adhesive and 0.1-20 parts of lubricants; the semipermeable film coating comprises 3-15 parts of semipermeable film coating material and 1 part of plasticizer; and the enteric coating comprises 35-65 parts of enteric coating material, 10-35 parts of plasticizer, 5-15 parts of surface active agent and 10-25 parts of antiplastering aid. The preparation has reasonable composition, better controlled-release effect, long effective duration, little gastrointestinal tract side effects, few influences of individual difference, high safety, and excellent patient compliance, and only needs to be taken twice one day. The invention also discloses a danshinolic acid B enteric controlled-release tablet preparation and a preparation method thereof.
Owner:TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE

Cardio-cerebral refreshing sustained-release soft capsules and preparation method thereof

The invention discloses cardio-cerebral refreshing sustained-release soft capsules and a preparation method thereof. The sustained-release soft capsules contain capsule shells and contents, wherein the contents contain the following active pharmaceutical ingredients in mass ratio: 390 parts of safflower oil, 3 parts of borneol, 17 parts of vitamin E and 65 parts of vitamin B; and the contents contain the following raw materials in parts by weight: 4.15 parts of active pharmaceutical ingredients and 2-8 parts of sustained-release coating material, wherein the sustained-release coating material is one or mixture of polyethylene glycol (PEG) and glyceryl monostearate based on an arbitrary proportion. The preparation method mainly comprises the following steps: grinding and evenly mixing 1/2-2/3 of the safflower oil in the active pharmaceutical ingredients and the other active pharmaceutical ingredients, and then, grinding and evenly mixing the residual safflower oil, the sustained-release coating material and a dispersing agent or a diluting agent; and evenly mixing the two obtained mixtures, and sieving with a 80-100 mesh sieve to obtain the capsule contents. The sustained-release soft capsules provided by the invention have the advantages that drug release can keep uniform and constant, drug action time can be prolonged, and a peak valley phenomenon can be avoided.
Owner:SHINEWAY PHARMA GRP LTD

Scutellaria baicalensis total flavonoid sustained release tablet and preparation method thereof

The invention discloses a scutellaria baicalensis total flavonoid sustained release tablet and a preparation method thereof, belonging to the field of Chinese medicine preparations. The scutellaria baicalensis total flavonoid sustained release tablet consists of the following components in percentage by weight: 20-50% of a scutellaria baicalensis total flavonoid extract, 20-40% of a sustained release framework material and 10-50% of pharmaceutical adjuvants, wherein the scutellaria baicalensis total flavonoid extract is determined through an ultraviolet spectrophotometry and contains not less than 60% of total flavonoid in terms of baicalin; a high performance liquid chromatography (HPLC) determines that content of a baicalin monomer is not less than 40%. In addition, the invention also discloses a method for preparing the scutellaria baicalensis total flavonoid sustained release tablet. The method mainly comprises the processes of extracting and separating the scutellaria baicalensis total flavonoid extract and preparing the sustained release tablet. Compared to a current commercial scutellaria baicalensis tablet, the scutellaria baicalensis total flavonoid sustained release tablet disclosed by the invention can significantly reduce a drug release speed, prolong release time and keep a stable blood concentration; moreover, the sustained release tablet can reduce administration time, reduce side effect and improve a medication compliance of patients.
Owner:LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products